To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Ex vivo alendronate local… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Ex vivo alendronate localization at the mesoporous titania implant/bone interface

Journal article
Authors Johan Karlsson
Necati Harmankaya
Stefan Allard
Anders Palmquist
Mats Halvarsson
Pentti Tengvall
Martin Andersson
Published in Journal of materials science. Materials in medicine
Volume 26
Pages article number 11
ISSN 1573-4838
Publication year 2015
Published at Institute of Clinical Sciences, Department of Biomaterials
Pages article number 11
Language en
Keywords bisphosphonate, alendronate, implant, titanium, drug delivery
Subject categories Biomaterials


An attractive approach in implant technology is local drug delivery, and design of efficient, safe and reliable treatments. Our hitherto strategy has been to coat Ti implants with a thin mesoporous TiO2 film that in turn is loaded with an osteoporosis drug, such as Alendronate (ALN) that is known to suppress osteoclastic activity. This system has proven highly successful and results in excellent osseointegration. However, more detailed information about drug-release and distribution at the bone/implant interface is needed. In this study, (14)C-ALN loaded titanium implants were placed up to 8 weeks into rat tibia and the spatial-temporal distribution of the drug was evaluated. Autoradiography data demonstrated a sustained release of (14)C-ALN and the released drug remained bound to bone in close vicinity, within 500 micrometers, of the implants. Liquid scintillation counting experiments confirmed that the distal transport of released (14)C-ALN was extremely low. The results are favorable as they show that ALN stays for a long time in the vicinity of the implant and may therefore improve for a long time the mechanical fixation of bone anchored implants. Moreover, these findings suggest due to the low systemic spreading a minimal risk of Alendronate related systemic side effects.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?